With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135034-10-5,3-Chloro-6-iodopyridazine,as a common compound, the synthetic route is as follows.
Procedure E: General Procedure of Negishi Coupling; A bromopyridine solution (1.6 eq.) in the freshly distilled and degassed THF is cooled to -78 C. in a three-neck round-bottom flask fitted with a condenser. The butyllithium (2.5 M in hexane, 1.6 eq.) is added gently and the reaction medium is stirred for 30 minutes at -78 C. The zinc chloride solution (previously sublimated, 1.6 eq.) in the degassed THF is cannulated at -78 C. into the reaction medium. The solution is stirred at room temperature for 30 minutes, then a solution of tetrakis(triphenylphosphine) palladium (0) (0.1 eq.) and halopyridazine (1 eq.) in the THF is cannulated into the reaction medium. The solution is stirred for 48 hours at a temperature that depends on the substrate. The medium is treated with a NaHCO3 saturated solution. The solution is filtered through Celite and sequentially washed with DCM and with concentrated ammonia (25 N). The organic phase is dried over Na2SO4 and concentrated under reduced pressure.; Route 3:; This synthetic route uses the Negishi coupling of an organozinc derivative with a halogenated pyridazine. The zinc pyridine is formed in situ from 2-bromopyridine in the presence of butyllithium and zinc chloride. A solution of 3-chloro-6-iodopyridazine (103) and tetrakis(triphenylphosphine) palladium (0) is then cannulated to give a compound (8a) with a yield of 62% (initial step). Bipyridazine (19) is achieved through homocoupling., 135034-10-5
As the paragraph descriping shows that 135034-10-5 is playing an increasingly important role.
Reference£º
Patent; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.; US2010/4443; (2010); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem